Drug Profile

KP 1196

Alternative Names: CD38 ARM- Biohaven Labs/PeptiDream; KP-1196

Latest Information Update: 28 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kleo Pharmaceuticals; PeptiDream
Developer Biohaven Labs; PeptiDream
Class Antineoplastics; Peptides
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Dec 2023 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Parenteral)
07 Jan 2021 Kleo Pharmaceuticals was acquired and merged into Biohaven Pharmaceutical Holding Company to form Biohaven Labs
30 Mar 2020 Pharmacodynamics data from a preclinical trial in Multiple myeloma released by Kleo Pharmaceuticals

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com